Multiple Myeloma News and Research

Latest Multiple Myeloma News and Research

PharmaMar to market and distribute APLIDIN drug candidate in Australia, New Zealand

PharmaMar has entered into an exclusive license and commercialization agreement with the pharmaceutical company Specialised Therapeutics Australia Pty (STA) to market and distribute the drug candidate APLIDIN (plitidepsin) in Australia and New Zealand.

20 Aug 2015

STA inks license and commercialisation agreement with PharmaMar for APLIDIN (plitidepsin)

Australian biopharmaceutical company Specialised Therapeutics Australia has struck an exclusive license and commercialisation agreement with European pharmaceutical partner company PharmaMar to market and distribute the novel oncology drug APLIDIN (plitidepsin) in Australia and New Zealand.

20 Aug 2015

MCRI announces winners of cancer crowdsourcing initiative

The Myeloma Crowd Research Initiative (MCRI), an unprecedented collaboration of cancer researchers and patient advocates, today announced the two winners of its first-ever crowdsourcing and patient-led initiative to fund research in high-risk multiple myeloma, a rare malignancy of plasma cells.

19 Aug 2015

$AbbVie's venetoclax Phase 2 trial meets primary endpoint in patients with relapsed/refractory CLL with 17P deletion$

AbbVie's venetoclax Phase 2 trial meets primary endpoint in patients with relapsed/refractory CLL with 17P deletion

AbbVie, a global biopharmaceutical company, today announced that a Phase 2 trial of its investigational medicine venetoclax met its primary endpoint of achieving overall response rates in patients with relapsed/refractory or previously untreated chronic lymphocytic leukemia (CLL) with 17p deletion, according to an independent review analysis.

12 Aug 2015

CRI commits $29.3 million in new funds to accelerate development of cancer immunotherapies

The Cancer Research Institute, a nonprofit organization dedicated to fueling the discovery and development of immunotherapies for all forms of cancer, announced that it has committed more than $29.3 million in new funds to accelerate cancer immunology research and cancer immunotherapy clinical development in the United States, Australia, Canada, France, Sweden, Switzerland, and The Netherlands.

5 Aug 2015

UVA Stem Cell Transplant Program receives FACT accreditation for autologous and allogeneic transplants

The Stem Cell Transplant Program at the University of Virginia Cancer Center has received international accreditation for its use of stem cells and bone marrow to treat patients with blood cancers.

3 Aug 2015

Array Biopharma reports strong fourth quarter and full year 2015 financial results

Array BioPharma Inc. today reported results for the fourth quarter and full year of its fiscal year ended June 30, 2015.

3 Aug 2015

FDA accepts Mundipharma EDO's Investigational New Drug Application for EDO-S101

Mundipharma EDO GmbH (Early Development in Oncology) is pleased to announce that the United States Food and Drug Administration has accepted the company's Investigational New Drug Application ("IND") for EDO-S101, a fusion molecule to treat relapsed/refractory haematologic malignancies and solid tumours.

31 Jul 2015

Amgen announces submission of supplemental New Drug Application to FDA for Kyprolis (carfilzomib)

Amgen today announced the submission of a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration for Kyprolis (carfilzomib) for Injection to seek an expanded indication for the treatment of patients with a form of blood cancer, relapsed multiple myeloma, who have received at least one prior therapy.

23 Jul 2015

PharmaMar, TTY Biopharm sign agreement to market and distribute APLIDIN (plitidepsin) in Taiwan

PharmaMar has entered into an exclusive license and commercialization agreement with the pharmaceutical company TTY Biopharm to market and distribute the drug candidate APLIDIN (plitidepsin) in Taiwan. Under the terms of the agreement, PharmaMar will receive an upfront payment, royalties and additional remunerations for regulatory milestones achieved by APLIDIN (plitidepsin).

23 Jul 2015

Genetic variation influences survival in patients with multiple myeloma

As part of a multi-institutional effort, researchers with Huntsman Cancer Institute at the University of Utah have found that multiple myeloma patients with a genetic variation in the gene FOPNL die on average 1-3 years sooner than patients without it.

23 Jul 2015

New TCR therapy demonstrates encouraging clinical responses in patients with multiple myeloma

Results from a clinical trial investigating a new T cell receptor (TCR) therapy that uses a person's own immune system to recognize and destroy cancer cells demonstrated a clinical response in 80 percent of multiple myeloma patients with advanced disease after undergoing autologous stem cell transplants (ASCT).

22 Jul 2015

Adaptimmune’s NY-ESO-1 TCR-engineered T-cell therapy mediates sustained antitumor effects in multiple myeloma patients

Adaptimmune Therapeutics plc, a clinical stage biopharmaceutical company focused on the use of T-cell therapy to treat cancer, today announced that data from its Phase I/II study of its affinity enhanced T-cell receptor therapeutic targeting the NY-ESO-1 cancer antigen in patients with multiple myeloma has been published in Nature Medicine.

22 Jul 2015

Patients' own genetically engineered immune cells show significant success against multiple myeloma

In recent years, immunotherapy has emerged as a promising treatment for certain cancers. Now this strategy, which uses patients' own immune cells, genetically engineered to target tumors, has shown significant success against multiple myeloma, a cancer of the plasma cells that is largely incurable.

21 Jul 2015

Abingdon Health seeks distributors for newly launched Seralite - FLC diagnostic device

Following the commercial launch of Seralite - FLC Abingdon Health is looking to appoint distributors in order to enable as many people as possible affected by multiple myeloma (a cancer arising from plasma cells) to have access to, and benefit from its rapid diagnostic capabilities.

17 Jul 2015

New research identifies potential treatment for primary effusion lymphoma

New research from the University of Southern California Norris Comprehensive Cancer Center has identified a potential treatment for a rare but previously incurable form of lymphoma that is observed primarily in patients with HIV/AIDS infection.

8 Jul 2015

SkylineDx’s MMprofiler test helps predict prognosis of patients with multiple myeloma

SkylineDx, an innovative biotechnology company specialising in the development and commercialization of genetic tests, is today launching its MMprofiler assay. This test enables clinicians to more accurately predict the prognosis of patients with multiple myeloma (bone marrow cancer) than traditional methods.

3 Jul 2015

BioLight receives CE Mark approval for CellDetect bladder cancer test

BioLight Life Sciences Investments Ltd., a firm that invests in, manages and commercializes biomedical innovations in ophthalmology and cancer diagnostics, announced today that its CellDetect non-invasive test for detecting bladder cancer in urine has obtained CE Marking, enabling the product to be marketed and sold in Europe and other territories.

30 Jun 2015

Solstice CEO honored with LLS's John Engdahl Award

Solstice's Chief Executive Officer Dr. Leonard Weiss has been honored by the Leukemia & Lymphoma Society with its John Engdahl Award. The award was established in recognition of John's dreams and his accomplishments of running and raising much needed funds for the Society.

26 Jun 2015

Current treatments for blood cancer priced too high to be considered cost-effective, new analysis finds

The costs associated with cancer drug prices have risen dramatically over the past 15 years, which is of concern to many top oncologists. In a new analysis, researchers at The University of Texas MD Anderson Cancer Center concluded the majority of existing treatments for hematologic, or blood, cancers are currently priced too high to be considered cost-effective in the United States.

23 Jun 2015

Multiple Myeloma News and Research

Latest Multiple Myeloma News and Research

PharmaMar to market and distribute APLIDIN drug candidate in Australia, New Zealand

STA inks license and commercialisation agreement with PharmaMar for APLIDIN (plitidepsin)

MCRI announces winners of cancer crowdsourcing initiative

AbbVie's venetoclax Phase 2 trial meets primary endpoint in patients with relapsed/refractory CLL with 17P deletion

CRI commits $29.3 million in new funds to accelerate development of cancer immunotherapies

UVA Stem Cell Transplant Program receives FACT accreditation for autologous and allogeneic transplants

Array Biopharma reports strong fourth quarter and full year 2015 financial results

FDA accepts Mundipharma EDO's Investigational New Drug Application for EDO-S101

Amgen announces submission of supplemental New Drug Application to FDA for Kyprolis (carfilzomib)

PharmaMar, TTY Biopharm sign agreement to market and distribute APLIDIN (plitidepsin) in Taiwan

Genetic variation influences survival in patients with multiple myeloma

New TCR therapy demonstrates encouraging clinical responses in patients with multiple myeloma

Adaptimmune’s NY-ESO-1 TCR-engineered T-cell therapy mediates sustained antitumor effects in multiple myeloma patients

Patients' own genetically engineered immune cells show significant success against multiple myeloma

Abingdon Health seeks distributors for newly launched Seralite - FLC diagnostic device

New research identifies potential treatment for primary effusion lymphoma

SkylineDx’s MMprofiler test helps predict prognosis of patients with multiple myeloma

BioLight receives CE Mark approval for CellDetect bladder cancer test

Solstice CEO honored with LLS's John Engdahl Award

Current treatments for blood cancer priced too high to be considered cost-effective, new analysis finds

Event guide: 4th Extra-Hepatic Lipid-Based Nanoparticles Delivery Summit eBook

Fluidics in Modern Healthcare & Medical Device Innovation

Scaling 3D biology: Automation, imaging, and the future of high-throughput research

How does norepinephrine influence anxiety-related behaviours?

Multiple Myeloma News and Research

Latest Multiple Myeloma News and Research

Event guide: 4th Extra-Hepatic Lipid-Based Nanoparticles Delivery Summit eBook

Fluidics in Modern Healthcare & Medical Device Innovation

Scaling 3D biology: Automation, imaging, and the future of high-throughput research

How does norepinephrine influence anxiety-related behaviours?

Newsletters you may be interested in